Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Biochemical Pharmacology

• Publication date

  2010-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bcp.2010.01.028PMID 20117100
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

  2008cited by this paper
• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin

  2008cited by this paper
• Different mechanisms for inhibition of human cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors.

  2007cited by this paper
• Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes.

  2007cited by this paper
• 8-Hydroxycannabinol: a new metabolite of cannabinol formed by human hepatic microsomes

  2006cited by this paper
• Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1.

  2006cited by this paper
• CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes.

  2005cited by this paper
• Chemical constituents of marijuana: the complex mixture of natural cannabinoids.

  2005cited by this paper
• Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol.

  2005cited by this paper
• In Vitro Inhibitory Effects of Cannabinoids on Progesterone 17α-Hydroxylase Activity in Rat Testis Microsomes

  2005cited by this paper
• Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and1B1

  2004cited by this paper
• Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers.

  2004cited by this paper
• Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?

  2001cited by this paper
• Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol.

  2001cited by this paper
• Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2.

  2001cited by this paper
• A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis.

  2001cited by this paper
• Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin.

  2001cited by this paper
• CYP3A4 is a major isoform responsible for oxidation of 7-hydroxy-Delta(8)-tetrahydrocannabinol to 7-oxo-delta(8)-tetrahydrocannabinol in human liver microsomes.

  2000cited by this paper
• CYP3A4 Is a Major Isoform Responsible for Oxidation of 7-Hydroxy-Δ8-tetrahydrocannabinol to 7-Oxo-Δ8-tetrahydrocannabinol in Human Liver Microsomes

  2000cited by this paper
• Effects of unsaturated side-chain analogs of tetrahydrocannabinol on cytochromes P450.

  2000cited by this paper
• Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane.

  2000cited by this paper
• Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1.

  1999cited by this paper
• Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator.

  1998cited by this paper
• Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2.

  1997cited by this paper
• Quantitative RT-PCR measurement of cytochromes p450 1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase expression in lung cells of smokers and nonsmokers.

  1997cited by this paper
• Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole.

  1997cited by this paper
• Oxidation of xenobiotics by recombinant human cytochrome P450 1B1.

  1997cited by this paper
• Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes.

  1996cited by this paper
• Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes.

  1996cited by this paper
• Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1.

  1996cited by this paper
• Theophylline metabolism in human liver microsomes: inhibition studies.

  1996cited by this paper
• Recent advances in the metabolism of cannabinoids.

  1995cited by this paper
• Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman.

  1995cited by this paper
• Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

  1994cited by this paper
• Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2.

  1994cited by this paper
• Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2.

  1994cited by this paper
• Characterization of cannabidiol-mediated cytochrome P450 inactivation.

  1993cited by this paper
• Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2.

  1993cited by this paper
• Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana.

  1992cited by this paper
• Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol.

  1992cited by this paper
• Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens.

  1992cited by this paper
• Characterization of human liver cytochromes P-450 involved in theophylline metabolism.

  1992cited by this paper
• Catalytic activity of cytochrome P450 isozymes purified from rat liver in converting 11-oxo-delta 8-tetrahydrocannabinol to delta 8-tetrahydrocannabinol-11-oic acid.

  1991cited by this paper
• Purification and characterization of the major hepatic cannabinoid hydroxylase in the mouse: a possible member of the cytochrome P-450IIC subfamily.

  1991cited by this paper
• Catalytic activity of cytochrome P450 isozymes purified from rat liver in converting 11-oxo-Δ8-tetrahydrocannabinol to Δ8-tetrahydrocannabinol-11-oic acid

  1991cited by this paper
• Single-dose kinetics of deuterium-labelled cannabinol in man after intravenous administration and smoking.

  1987cited by this paper
• Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat.

  1986cited by this paper
• Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.

  1985cited by this paper
• The cannabinoids: chemical, pharmacologic, and therapeutic aspects.

  1984cited by this paper
• SINGLE DOSE KINETICS OF CANNABIDIOL IN MAN1

  1984cited by this paper
• Metabolic and psychophysiologic studies of cannabidiol‐hexobarbital interaction

  1980cited by this paper
• Cannabidiol--antiepileptic drug comparisons and interactions in experimentally induced seizures in rats.

  1977cited by this paper
• Metabolism and distribution of cannabinoids in rats after different methods of administration.

  1973cited by this paper
• Interactions of several cannabinoids with the hepatic drug metabolizing system.

  1973cited by this paper
• Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism

  1972cited by this paper
• Forensic chemical study on marihuana. I. A detection method of the principal constituents by thin-layer and gas chromatographies.

  1968cited by this paper

• Cannabidiol - a friend or a foe?

  2025cites this paper
• Molecular targets of cannabinoids and their derivatives in epilepsy – a review with focus on CBD

  2025cites this paper
• The Pharmacological Profile of Plant-Derived Cannabinoids In Vitro.

  2025cites this paper
• trans-Styrylquinazolinone CYP1B1 inhibitors as potential therapeutics in A549 cells.

  2025cites this paper
• Discovery and synthesis of azepinoindoles as novel hCYP1B1 inhibitors with AhR-independent anticancer activity.

  2025cites this paper
• Cannabinoids and the endocannabinoid system in the regulation of cytochrome P450 metabolic activity-a review

  2025cites this paper
• Beyond the hype: a comprehensive exploration of CBD’s biological impacts and mechanisms of action

  2025cites this paper
• Cannabidiol and Δ9-tetrahydrocannabinol induce drug-metabolizing enzymes, but not transporters, in human hepatocytes: Implications for predicting complex cannabinoid-drug interactions.

  2025cites this paper
• Analysis of six CYP450 genetic variants regarding the response to cannabidiol combined with anticonvulsant medication in mexican patients with drug-resistant epilepsy

  2025cites this paper
• Design of Novel 2-Phenylquinazolin-4-amines as Selective CYP1B1 Inhibitors for Overcoming Paclitaxel Resistance in A549 Cells.

  2024cites this paper
• Health benefits, pharmacological properties, and metabolism of cannabinol: A comprehensive review

  2024cites this paper
• Cannabinoid-Induced Inhibition of Morphine Glucuronidation and the Potential for In Vivo Drug–Drug Interactions

  2024cites this paper
• Molecular Targets for Cannabinoids in Natural Killer Cells: Do They Modulate the Antitumor Activity?

  2024cites this paper
• Development of novel N-aryl-2,4-bithiazole-2-amine-based CYP1B1 degraders for reversing drug resistance.

  2024cites this paper
• Examining the hepatotoxic potential of cannabidiol, cannabidiol‐containing hemp extract, and cannabinol at consumer‐relevant exposure concentrations in primary human hepatocytes

  2024influential citation
• The Efficacy of Cannabis in Oncology Patient Care and Its Anti-Tumor Effects

  2024cites this paper
• Enhancing Cannabis Extraction Efficiency and Sustainability through Quantum Computing: A Review

  2023cites this paper
• Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism resulting in the potential for drug-drug interactions

  2023cites this paper
• Phytochemical Comparison of Medicinal Cannabis Extracts and Study of Their CYP-Mediated Interactions with Coumarinic Oral Anticoagulants

  2023cites this paper
• Cannabidiol reduces fall armyworm (Spodoptera frugiperda) growth by reducing consumption and altering detoxification and nutritional enzyme activity in a dose-dependent manner

  2023cites this paper
• Electrochemical Cross-Dehydrogenative Coupling of Isochroman and Unactivated Ketones.

  2023cites this paper
• Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions

  2023cites this paper
• The Polypharmacological Effects of Cannabidiol

  2023cites this paper
• Evaluation of Cytochrome P450‐Mediated Cannabinoid‐Drug Interactions in Healthy Adult Participants

  2023cites this paper
• CYP1A inhibitors: Recent progress, current challenges, and future perspectives

  2023cites this paper
• Drug interactions with Cannabis sativa: Mechanisms and clinical implication

  2023cites this paper
• "Various approaches to postmarketing drug safety monitoring"

  2022cites this paper
• Cannabinoid-Based Medicine: Pharmacology and Drug Interactions

  2022cites this paper
• Design, Synthesis and In Vivo Fluorescence Imaging Study of a Cytochrome P450 1B1 Targeted NIR Probe Containing a Chelator Moiety

  2022cites this paper
• Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes

  2022cites this paper
• A new class of CYP1B1 inhibitors derived from bentranil.

  2022cites this paper
• Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy

  2022influential citation
• Cannabis, Cannabinoids and Cannabis-Based Medicines in Cancer Care

  2022cites this paper
• Cannabidiol drug interaction considerations for prescribers and pharmacists

  2022cites this paper
• Complementary medicines used in ulcerative colitis and unintended interactions with cytochrome P450-dependent drug-metabolizing enzymes

  2022influential citation
• Cannabinoids, insomnia, and other sleep disorders.

  2022cites this paper
• Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization

  2021influential citation
• Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions

  2021cites this paper
• Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions

  2021cites this paper
• Medicinal Cannabis: an overview for health-care providers

  2021cites this paper
• Synthetic and Natural Derivatives of Cannabidiol.

  2021cites this paper
• A systematic review of possible interactions for herbal medicines and dietary supplements used concomitantly with disease‐modifying or symptom‐alleviating multiple sclerosis drugs

  2021cites this paper
• Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC

  2021cites this paper
• Design, Synthesis and Binding Affinity Evaluation of Cytochrome P450 1B1 Targeted Chelators.

  2021cites this paper
• Biosynthesis and synthetic biology of psychoactive natural products.

  2021cites this paper
• The Pharmacology of Cannabinoids

  2021cites this paper
• Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions

  2021cites this paper
• α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship.

  2021cites this paper
• Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites

  2021cites this paper
• Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions

  2021influential citation
• Cannabis chemistry, post-harvest processing methods and secondary metabolite profiling: A review

  2021cites this paper
• Analgesic Potential of Terpenes Derived from Cannabis sativa

  2021cites this paper
• Routes of Administration, Pharmacokinetics and Safety of Medicinal Cannabis

  2021cites this paper
• Cannabidiol safety

  2021cites this paper
• Direct‐acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV‐infected patients

  2020cites this paper
• Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19

  2020cites this paper
• Direct‐acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV‐infected patients

  2020cites this paper
• Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions

  2020cites this paper
• Cannabinol in the spotlight: Toxicometabolomic study and behavioral analysis of zebrafish embryos exposed to the unknown cannabinoid.

  2020cites this paper
• Evaluation of pharmacokinetics and acute anti‐inflammatory potential of two oral cannabidiol preparations in healthy adults

  2020cites this paper
• Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation.

  2020cites this paper
• Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use?

  2020cites this paper
• The Impact of Cannabidiol on Psychiatric and Medical Conditions

  2020influential citation
• Influences of phytocannabinoids on drug-drug interactions and their clinical implications.

  2020influential citation
• A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies

  2020cites this paper
• Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)

  2020cites this paper
• Special Section on Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P45

  2020cites this paper
• Mechanism-based inactivation of cytochrome P450 enzymes by natural products based on metabolic activation

  2020cites this paper
• Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450

  2020influential citation
• Plant derived versus synthetic cannabidiol: Wishes and commitment of epilepsy patients.

  2020cites this paper
• In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes and Drug Transporters

  2020cites this paper
• The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats

  2020cites this paper
• In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites

  2019cites this paper
• Direct and Efficient C( sp 3 )‐H Bond Alkylation of Tetrahydroisoquinolines and Isochroman with Alkylzinc Reagents

  2019cites this paper
• A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.

  2019cites this paper
• Cannabis Hyperemesis Syndrome in Palliative Care: A Case Study and Narrative Review

  2019cites this paper
• Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use

  2019cites this paper
• In Vitro Inhibitory Effects of APINACA on Human Major Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Drug Transporters

  2019cites this paper
• The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.

  2019cites this paper
• Cannabinoids-Human Physiology and Agronomic Principles for Production

  2019cites this paper
• Synthetic cannabinoids are substrates and inhibitors of multiple drug-metabolizing enzymes

  2018cites this paper
• Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2.

  2018cites this paper
• Dermatology-Related Uses of Medical Cannabis Promoted by Dispensaries in Canada, Europe, and the United States

  2018cites this paper
• Study on the interaction between cannabinol and DNA using acridine orange as a fluorescence probe

  2018cites this paper
• Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review

  2018cites this paper
• Pharmakologische Grundlagen: Das Schicksal psychoaktiver Substanzen im menschlichen Körper

  2018cites this paper
• Effects of Δ9-tetrahydrocannabinol on irinotecan-induced clinical effects in rats.

  2018cites this paper
• Design, Synthesis, and Biological Evaluation of Cytochrome P450 1B1 Targeted Molecular Imaging Probes for Colorectal Tumor Detection.

  2018cites this paper
• Synthesis and biological evaluation of 1-amino isochromans from 2-bromoethyl benzaldehyde and amines in acid medium.

  2018cites this paper
• Direct Arylation of Benzyl Ethers with Organozinc Reagents.

  2018cites this paper
• Cancer chemoprevention revisited: Cytochrome P450 family 1B1 as a target in the tumor and the microenvironment.

  2018cites this paper
• Development of 2-arylbenzo[h]quinolone analogs as selective CYP1B1 inhibitors

  2018cites this paper
• A Specific Probe Substrate for Evaluation of CYP4A11 Activity in Human Tissue Microsomes and a Highly Selective CYP4A11 Inhibitor: Luciferin-4A and Epalrestat

  2018cites this paper
• Appendix C: References (Part I)

  2018cites this paper
• Computational systems pharmacology analysis of cannabidiol: a combination of chemogenomics-knowledgebase network analysis and integrated in silico modeling and simulation

  2018cites this paper
• In Vitro Inhibitory Effects of Synthetic Cannabinoid EAM-2201 on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes

  2018cites this paper
• Part I: Current Legislation, Scientific Literature Review, and Nursing Implications

  2018cites this paper
• Cannabidiol modulation of antinociceptive tolerance to Δ9-tetrahydrocannabinol

  2018cites this paper
• Inhibition of cytochrome P450 and uridine 5′-diphospho-glucuronosyltransferases by MAM-2201 in human liver microsomes

  2017cites this paper
• Pharmacotherapy of Chronic Pain

  2017cites this paper